Advitech Inc.

Advitech Inc.

November 16, 2006 16:47 ET

Celebrated Former Canadian Olympian Pierre Harvey to Promote Advitech's Dermylex'TM' Product

QUEBEC CITY, QUEBEC--(CCNMatthews - Nov. 16, 2006) - Advitech Inc. (TSX VENTURE:AVI), one of Canada's leading health sciences and technology companies, today announced that an agreement has been reached with celebrated former Canadian Olympian Pierre Harvey to promote the benefits of the Company's award-winning Dermylex™ psoriasis remedy.

Mr. Harvey, who is amongst an estimated one million Canadians who suffer from psoriasis, is best known as the first Canadian male athlete to compete in both the 1984 Summer Olympics (cycling) and the 1984 Winter Olympics (cross-country skiing). In 1988, he was named a member of the Order of Canada. Mr. Harvey has since been inducted into the Canadian Ski Hall of Fame (1992), Canadian Cycling Hall of Fame (2006) and Canadian Olympic Association Hall of Fame (2006).

"Suffering from mild to moderate psoriasis for many years, I heard about Dermylex and decided to try it to see for myself its effect on this disease," said Mr. Harvey. "Very rapidly, my psoriasis has improved after taking Dermylex, a natural health product clinically proven and scientifically supported to relieve mild to moderate psoriasis symptoms. I agreed to promote the product because of my personal confidence in the product and its proven effectiveness, in my case. Dermylex simply works very well."

"This relationship with Pierre will permit Advitech to speak to Canadians about Dermylex with authority while educating them about psoriasis in plain-spoken terms," explained Renaud Beauchesne, President and Chief Executive Officer, Advitech Inc. "It's an important step in our plan to increase our distribution, sales and market share growth of Dermylex in Canada."

Developed by Advitech and distributed by Jamieson Laboratories, Dermylex is a patented blend of bioactive peptides from a natural source, with properties that have been rigorously demonstrated through scientific studies. It acts as an immune system regulator in auto-immune diseases such as psoriasis. During clinical trials, patients who responded to Dermylex generally began to see an improvement within 56 days.

Dermylex is not a topical treatment, but a tablet taken orally. This makes treatment more convenient. It is also a product of natural origin. Its effectiveness has been demonstrated using the same rigorous parameters as is used for pharmaceuticals, but it features the safety profile of natural health products.

Dermylex is available in drug stores and does not require a prescription. The dosage is one 400 mg (milligram) tablet taken twice daily before meals. Dermylex does not replace other treatments recommended by a patient's health specialist. Patients allergic to dairy products must not use this product.

Dermylex is available at selected pharmacies and drug stores in Quebec and in other provinces at a manufacturer's suggested list price of $59.95.

About Advitech

Advitech is a life science and technology Company with the mission of discovering and commercializing scientifically supported, patented natural health products. Effective and safe, these products are designed to help counter Immune-Mediated Inflammatory Disorders (IMID), such as psoriasis and inflammatory bowel diseases. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54 799 818. The NEW Dermylex™ website is now online at

About Jamieson Laboratories

Established in 1922, Jamieson Laboratories is Canada's largest manufacturer and distributor of advanced natural health care products. Jamieson's state-of-the-art pharmaceutical manufacturing laboratories are located in Windsor, Ontario. The company is a world leader in the vitamin and nutrition industry, exporting to over 45 countries including the USA, China, Japan, Hong Kong, Korea and Singapore. For more information, please visit the Jamieson Laboratories website at or call 1 800 265-5088.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information